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Abstract- Hypoxia inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitors are 
shown to be protective in several models of inflammatory bowel disease (IBD). 
However, these non-selective inhibitors are known to inhibit all the three isoforms of 
PHD i.e. PHD-1, PHD-2 and PHD-3. In the present report, we investigated the 
associated changes in levels of PHDs during the development and recovery of 
chemically induced colitis in mice. The results indicated that in the experimental model 
of murine colitis, levels of both, PHD-1 and PHD-2 were found to be increased with 
progression of the disease; however, the level of PHD-3 remained the same in group 
of healthy controls and mice with colitis. Thus, the findings advocated that inhibitors, 
which inhibited all three isoforms of PHD could not be ideal therapeutics for IBD since 
PHD-3 is required for normal gut function. Hence this necessitates the development 
of new compounds capable of selectively inhibiting PHD-1 and PHD-2 for effective 
treatment of IBD. 
Keywords: Prolyl hydroxylases, Inflammatory bowel disease, Colitis, Disease activity 
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INTRODUCTION 
Hypoxia inducible factor (HIF)-prolyl hydroxylases (PHDs) are member of 
dioxygenase enzymes family. These enzymes are known to play an important function 
in intracellular oxygen sensing as well as signalling responses in low oxygen levels 
(hypoxia). This occurs  mainly by the regulation of HIF stability [1-4]. These PHDs 
consist of three isoforms (PHD-1, PHD-2 and PHD-3), which share mostly similar 
biochemical characteristics, however all three isoforms of PHDs are known to have 
very distinct and tissue-specific expression profiles and, regulation of HIF, which in 
turn can affect pro-survival signalling pathways, including nuclear factor κB pathways 
during inflammation [1, 5-7]. These PHDs are known to mediate their effect on HIF 
pathway via hydroxylation of proline residues of the HIF subunit, which is degraded 
under normoxic condition. Once it is hydroxylated, HIF acts as a target for 
ubiquitylation by von Hipple Lindau E3 ubiqutitin ligase and results in the degradation 
and ubiquitination of HIF [8]. The PHDs perform a pivotal function in adaptive 
response known to occur during hypoxia via the activation of several pathways of 
genes expression implicated in support of cell survival, erythropoiesis, angiogenesis 
and metabolism. These features make PHD an interesting target for therapy [9].  
Inflammatory bowel disease (IBD), an idiopathic disease with genetically 
heterogenous nature, has chronic inflammatory conditions in the gastrointestinal tract 
(GIT) with severe pathology and limited therapeutic options [10-12]. Till date the 
underlying causes of IBD are not well defined, however the fundamental defect in this 
disease involves damage/injury of the intestinal epithelial barrier resulting in the 
development and progression of the disease. Hence targeting of the HIF-PHD 
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pathway may be a fascinating area for potential future therapeutics for inflammatory 
disease. 
Various reports employing pharmacological inhibition of hydroxylase enzyme 
revealed improvisation in variety of inflammatory conditions including IBD [13, 15]. 
Several researchers reported that pan-hydroxylase inhibitors such as 
dimethyloxalylglycine (DMOG) have a protective effect in experimental colitis [13-15]. 
However, majority of these studies have not identified the actual isoform of PHDs or 
the effector pathways involved in this protective effect.   
Our previous findings suggested that there was increased PHD-1 level in 
patients with active ulcerative colitis and genetic loss of PHD-1 was found to be 
protective in experimental colitis [16]. However, since there are three isoforms of PHDs 
it would be of interest for researchers to know how the levels of PHDs change during 
disease development and recovery in IBD. Thus to answer this query, the present 
study has been framed to examine the changes in levels of PHDs (PHD-1, -2 and -3) 
during the inflammation development and its progression in experimental model of 
murine colitis. 
MATERIALS AND METHODS  
Dextran Sodium Sulphate (DSS) Induced Colitis  
Colitis was induced in female C57/Bl6 mice using our previously established 
protocol [15, 17]. Briefly, 2.5% w/v dextran sodium sulphate (DSS) was administered 
in mice via drinking water to induce colitis. Colon tissues were taken at days 2, 3, 4, 
5, 6 and 7 from mice exposed to 2.5% w/v DSS in drinking water. The mice of recovery 
group were exposed to 2.5% w/v DSS in drinking water for 5 days and allowed to 
recover naturally for next 5 days. On the 10th day, colon tissue was collected from this 
group.  
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Assessment of Prolyl Hydroxylases (PHD) Levels 
The colon tissue lysates were analysed for the level of protein expression of 
PHD-1, -2 and -3 levels by Western blotting technique as reported previously [16].  
Disease Activity Index (DAI) 
The weight of each animal was recorded on a daily basis. The stool consistency 
and appearance of faecal blood was monitored. These parameters were converted in 
to Disease Activity Index (DAI) as illustrated previously [18].  
Colon Length  
Each excised colon length was recorded after removal of the faecal matter 
using a cotton swap dipped in phosphate buffer saline (PBS) solution following 
previously reported method [15, 18].  
Statistical Analysis 
Analysis of variance (ANOVA) or Student t test was employed for statistical 
comparisons and data was represented as mean±standard deviation (mean±SD). 
RESULTS AND DISCUSSION 
The DAI scores indicated that administration of DSS in drinking water caused 
weight loss, diarrhoea and appearance of blood in faeces, since the DAI steadily 
raised from day 2 onwards indicating the onset of inflammation from day 2 (Fig. 1a). 
We have also noted that colon length of mice progressively decreased as the 
inflammation progressed (Fig. 1b). This could be due to muscle wasting of the colon 
tissue during inflammation. Furthermore, both the DAI score and colon length 
indicated that withdrawal of DSS from drinking water resulted in tissue recovery and 
alleviation of the classical symptoms of colitis (Fig. 1).  
Our key results indicated that PHD-1 level was found to be lower than that of 
the healthy control at day 2 and it gradually increased by day 5 (Fig. 2). This event 
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suggested that PHD-1 expression levels initially decreased when inflammation sets in 
and then progressively increased as the inflammation was established due to 
administration of DSS in drinking water. The recovery group has shown the highest 
level of PHD-1 expression in colon tissue (Fig. 2a), suggesting that once the PHD-1 
level is elevated due to inflammation is does not go down even after the withdrawal of 
DSS. The PHD-2 levels followed a similar decline trend at day 2 followed by an 
increase at day 5. In case of PHD-2, the recovery group also showed the highest levels 
in the colonic tissue (Fig. 2b). Contrary to this, the levels of PHD-3 were observed to 
be constant in healthy control, recovery group and during the course of disease 
progression (Fig. 2c). It suggested that PHD-3 has not involved in development and 
progression of inflammation during experimental colitis.  
The upregulated PHD-1 in colonic biopsies of IBD patients illustrated the 
correlation between PHD1 expression and disease severity in patients [16, 19]. 
Among PHD-1, -2 and -3, only PHD-1 deficient mice were found to be selectively 
protected against DSS-induced colitis development advocating an affirmative function 
of PHD-1 in the management of intestinal epithelial cell apoptosis and preservation of 
epithelial barrier during intestinal inflammation [16]. The hypothesized link between 
improved barrier function and consequent protection against the colitis development 
was also supported by studies performed in other models indicating an antiapoptotic 
effect of pharmacologically inhibited hydroxylase enzyme [20-22] 
 
 
 
 
CONCLUSION  
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These results suggest that PHD-3 isoform is expressed in healthy as well as 
diseased colon tissue, indicating that PHD-3 is required for the normal function of the 
gut. However, PHD-1 and -2 expression levels fall when inflammation is initiated and 
gradually increases during progression of inflammation and is observed to be the 
highest in chronic stages. The recovery group indicates that once the agent causing 
inflammation of the colon i.e. DSS is removed from the drinking water, these mice 
show signs of recovery (Fig. 1), however the increased levels of PHD-1 and -2 are not 
reduced to normal level, which suggest that PHD-1 and -2 are involved in chronic 
inflammatory stages of the disease. These findings advocate that inhibition of all PHDs 
using a non-selective prolyl hydroxylases inhibitor may not be the best strategy 
towards the development of new therapeutics for IBD. Hence strategies to selectively 
target PHD-1 and -2 are warranted leading to an improved therapeutic advancement 
in the field of IBD treatment. 
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performed under UK Home Office personal and project licence  
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Fig. 1. Changes in disease activity score (DAI) and colon length during active colitis. 
In a, the composite score of weight loss, stool consistency and blood in faeces during 
disease progression was represented, and in b, the changes of colon length during 
active colitis were given. *Each control and experimental group contained a minimum 
of n=6 mice. 
Fig. 2. Colon homogenates assessed for (a) PHD-1, (b) PHD-2 and (c) PHD-3 protein 
levels. Each control and experimental group contained a minimum of n=6 mice. PHD-
1 level was found to be increased with disease progression in murine model of colitis. 
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